Strategic Review of Essa Pharma: Potential 27% Upside Amidst Halted Trials and Strong Shareholder Alignment
Essa Pharma (EPIX) halted pipeline development, launched a strategic review, with NAV/liquidation value estimated at $2.18/share.
131 Views
EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS Increasing Valuation to 33 per Share
On September 13, 2024, ESSA Pharma Inc. (EPIX) announced that updated dose escalation data for the ongoing Phase 1/2 clinical trial of masofaniten...
208 Views
EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024
On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and...
113 Views
EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24
On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and...
219 Views
SSI Weekly: Galaxy Gaming Acquisition and Other Portfolio Updates
Galaxy Gaming is being acquired by Evolution AB for $3.20/share, with a 17% spread and minimal regulatory hurdles. Other updates follow.
137 Views